Additionally, monoclonal antibody-based therapies, such as trastuzumab, have shown limited clinical benefits in HER2-mutant NSCLC when used as monotherapy (Cooper and Gainor, 2022), likely due to insufficient tumor penetration and inadequate downstream signaling blockade. Here, ERBB2 is linked to non-small cell lung carcinoma.